Xintela’s goal is to create significant medical advances in the fields of regenerative medicine and cancer, with particular focus on the treatment of cartilage damage and brain tumours.
Xintela AB is a Swedish biomedical company working in the fields of regenerative medicine and cancer, with particular focus on cartilage damage and brain tumours.
The key to Xintela’s operations is the company’s patented marker technology XINMARK®. Xintela’s markers are specific proteins which work as ”recognition flags” on the surface of certain cells. The markers make it possible to identify and select certain types of stem cells which can develop into cartilage cells. Thus, Xintela can provide a unique way of ensuring the quality of stem cells to be used in repairing damaged cartilage. XINMARK® technology also makes it possible to detect certain tumour cells and target a treatment to those cells to slow the tumour growth.
Xintela was founded in 2009 by the company’s CEO Evy Lundgren-Åkerlund. The company’s operations are based on many years of research and development undertaken by Evy and her team at the University of Lund and in Cartela AB.
In 2013, Xintela initiated its research and development operations with a focus on developing stem cell products for the repair of damaged cartilage. In 2014, research and development work in the field of brain tumour treatment was initiated.
Xintela has a broad and strong patent portfolio, including over 50 approved patents in important markets such as Australia, Europe, USA, Canada and Japan.
Xintela’s management team and Board have extensive experience from the Life Sciences industry, covering research and development of medical products in both preclinical and clinical phases. Also, the Board has broad experience within the field of regenerative medicine and possesses a wealth of knowledge and competence in the fields of economics and law.
Ph.D in medical sciences and Assoc. Professor.
Chief Executive Officer since 2009. Founder of Xintela, with a long experience of biomedical research and development. Has previously had leading roles in both academia and industry. Founded Cartela AB and was CEO and research director from 2000 to 2007. Was Head of Operations/CEO for Ideon Bioincubator/Lund Life Science incubator from 2008 to 2012.
BSc Economics
Has held numerous positions as head of economics, both in Sweden and internationally and has operated his own auditing firm for more than 10 years. Gunnar Telhammar is currently working with Xintela as a consultant.
LL.M, J.D., B.Sc. (Econ)
Strategic advisor and chairman of the board since 2011. Extensive experience from the pharmaceutical, biotechnical and medical technical industries, such as CEO for Pulsetten AB (which sold DuoCort Pharma AB to ViroPharma Inc in 2011) and a partner in PULS (Partners for Development investments in Life Sciences). Board chairman for Saga Diagnostics AB, Monocl AB and ImmuneBiotech Medical Sweden AB.
PhD in medical sciences and associate professor
Business Development Manager since April 2017. Has broad experience of Business Development in Life Science. He has been Business Development Manager at Invest in Skåne AB and has been a member of the board at Minervax ApS, as well as advisor to Enzymatica AB. He also has a broad background in biomedical research, including as research group leader, with focus on Medical Microbiology and Immunology.
LL.M, J.D., B.Sc. (Econ)
Strategic advisor and chairman of the board since 2011. Extensive experience from the pharmaceutical, biotechnical and medical technical industries, such as CEO for Pulsetten AB (which sold DuoCort Pharma AB to ViroPharma Inc in 2011) and a partner in PULS (Partners for Development investments in Life Sciences). Board chairman for Saga Diagnostics AB, Monocl AB and ImmuneBiotech Medical Sweden AB.
MD, Orthopedic surgeon
Board member since 2014. Extensive experience in cell therapy and currently Vice President and Head of Development for the gene therapy department of GlaxoSmithKline (GSK). Previously, leading clinical and regulatory positions in regenerative medicine departments in Sanofi Biosurgery and Genzyme as well as holding positions of medical and regulatory responsibility in Geistlich Pharma.
Pharmacist, PhD, Professor
Board member since 2013. Extensive experience with investment activities from several venture capital companies. Has experience as CEO or board membership of several smaller life science companies in Sweden and Denmark, was Vice President Preclinical Research at Astra Pain Control and Astra Draco, was Senior Vice President Preclinical and Clinical research at Pharmacia and Pharmacia UpJohn (Milano and Stockholm). Board chairman for AroCell AB (publ).
Pharmacist
Board member since 2014. Advisor in life sciences industry. Previously Global Head for AstraZeneca’s Clinical Research. Board member in Mevia AB, T-bolaget AB, PULS, Adenovir Pharma AB, Xbrane Bioscience AB and Swecure AB.
An important part of Xintela’s business strategy is to collaborate with leading research groups and other companies. Through these collaborations, Xintela can both create interest for the company’s technology and, at the same time, generate income through licencing. Xintela has already initiated several national and international collaborations with players in the fields of regenerative medicine and cancer.
There are currently no open positions but we are always interested in receiving spontaneous applications. If you believe you can contribute new competencies and energy to our dynamic team, send your CV to evy@xintela.se.
